Skip to main content

Advertisement

SpringerLink
Log in

Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Main Purpose

This study aimed to determine any association of KRAS and BRAF mutations in colorectal cancer with clinicopathological features and overall survival (OS) of Southeast Iranian colorectal cancer (CRC) patients.

Methods

Overall, KRAS and BRAF status were assessed in 100 Iranian CRC subjects. A hundred consecutive stages I–IV CRC patients, who underwent surgical tumor resection from February 2012 to August 2015, were prospectively attained from three centers and were enrolled in the research. Direct sequencing and real-time PCR methods were used to the detection of KRAS and BRAF mutations, respectively. Logistic regression models were used to detect associations of KRAS and BRAF mutations with clinical/clinicopathological features. Kaplan–Meier model was used to estimate overall survival.

Results

In total, KRAS and BRAF mutations were detected in 29 (29%) and 7 (7%) of 100 CRC patients, respectively. BRAF mutations that all comprised V600E and KRAS mutations were found in codon 12, 13, and 61 (72.4%, 20.7 and 6.9%), respectively. In a multivariate analysis, older age (≥ 60) was significantly associated with higher KRAS mutations rate and high BRAF mutation rate was significantly associated with older age (≥ 60) and poorly differentiated tumors. KRAS and BRAF mutant vs. wild type of KRAS and BRAF, 5-year OS was 62.1% vs. 71.8% (p value > 0.05) and 57.1% vs. 67.7% (p value > 0.05), respectively.

Conclusion

Mutations were found in both KRAS and BRAF genes in Iranian colorectal cancers patients and were associated with clinical/clinicopathologic features. Our data emphasizes the importance of these molecular features in Iranian CRC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. https://doi.org/10.1002/ijc.29210.

    Article  CAS  PubMed  Google Scholar 

  2. Azadeh S, Moghimi-Dehkordi B, Fatemi SR, Pourhoseingholi MA, Ghiasi S, Zali MR. Colorectal cancer in Iran: an epidemiological study. Asian Pacific J Cancer Prev. 2008;9:123–6.

    Google Scholar 

  3. Eklöf V, Wikberg ML, Edin S, Dahlin AM, Jonsson BA, Öberg Å, Rutegård J, Palmqvist R. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer. 2013;108:2153–63. https://doi.org/10.1038/bjc.2013.212.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ren J, Li G, Ge J, Li X, Zhao Y. Is K-ras gene mutation a prognostic factor for colorectal Cancer. Dis Colon rectum. 2012;55:913–23. https://doi.org/10.1097/DCR.0b013e318251d8d9.

    Article  PubMed  Google Scholar 

  5. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009;27:5931–7. https://doi.org/10.1200/JCO.2009.22.4295.

    Article  CAS  PubMed  Google Scholar 

  6. Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, Sorich MJ. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015;112:1888–94. https://doi.org/10.1038/bjc.2015.173.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, Cabiddu M, Iacovelli R, Bossi I, Lonati V, Ghilardi M, De Braud F, Barni S. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. 2015;51:587–94. https://doi.org/10.1016/j.ejca.2015.01.054.

    Article  CAS  PubMed  Google Scholar 

  8. Baldus SE, Schaefer K-L, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 2010;16:790–9. https://doi.org/10.1158/1078-0432.CCR-09-2446.

    Article  CAS  PubMed  Google Scholar 

  9. Jayasekara H, English DR, Haydon A, Hodge AM, Lynch BM, Rosty C, Williamson EJ, Clendenning M, Southey MC, Jenkins MA, Room R, Hopper JL, Milne RL, Buchanan DD, Giles GG, MacInnis RJ. Associations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype. Int J Cancer. 2018;142:238–50. https://doi.org/10.1002/ijc.31049.

    Article  CAS  PubMed  Google Scholar 

  10. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst. 2010;102:365–7. https://doi.org/10.1093/jnci/djq031.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Nazemalhosseini-Mojarad E, Kishani Farahani R, Mehrizi M, Baghaei K, Yaghoob Taleghani M, Golmohammadi M, Peyravian N, Ashtari S, Pourhoseingholi MA, Asadzadeh Aghdaei H, Zali MR. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability. In: Prognostic value of BRAF and KRAS mutation in relation to colorectal cancer survival in Iranian patients: correlated to microsatellite instability. Cancer: J. Gastrointest; 2019. https://doi.org/10.1007/s12029-019-00201-4.

    Chapter  Google Scholar 

  12. Shahriari-Ahmadi A, Ansarinejad N, Fardad F, Abbaszadeh M, Sadeghi M. KRAS and NRAS testing in metastatic colorectal cancer in Central Iran (Tehran): a review on literature of the middle east. Indian J Med Paediatr Oncol. 2018;39:210. https://doi.org/10.4103/ijmpo.ijmpo_133_17.

    Article  Google Scholar 

  13. Payandeh M, Shazad B, Sadeghi M, Shahbazi M. Correlation between RAS test results and prognosis of metastatic colorectal cancer patients: a report from Western Iran. Asian Pac J Cancer Prev. 2016;17:1729–32. https://doi.org/10.7314/apjcp.2016.17.4.1729.

    Article  PubMed  Google Scholar 

  14. S. Jancik, J. Drabek, J. Berkovcova, Y.Z. Xu, M. Stankova, J. Klein, V. Kolek, J. Skarda, T. Tichy, I. Grygarkova, D. Radzioch, M. Hajduch, A comparison of Direct sequencing, Pyrosequencing, High resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas, J. Exp. Clin. Cancer Res. 31 (2012). https://doi.org/10.1186/1756-9966-31-79.

  15. Rechsteiner M, Von Teichman A, Rüschoff JH, Fankhauser N, Pestalozzi B, Schraml P, Weber A, Wild P, Zimmermann D, Moch H. KRAS, BRAF, and TP53 deep sequencing for colorectal carcinoma patient diagnostics. J Mol Diagnostics. 2013;15:299–311. https://doi.org/10.1016/j.jmoldx.2013.02.001.

    Article  CAS  Google Scholar 

  16. Harari PM, Allen GW, Bonner JA. Biology of interactions: Antiepidermal growth factor receptor agents. J Clin Oncol. 2007;25:4057–65. https://doi.org/10.1200/JCO.2007.11.8984.

    Article  CAS  PubMed  Google Scholar 

  17. Bisht S, Ahmad F, Sawaimoon S, Bhatia S, Das BR. Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma. Med Oncol. 2014;31:124. https://doi.org/10.1007/s12032-014-0124-3.

    Article  CAS  PubMed  Google Scholar 

  18. Zhang J, Zheng J, Yang Y, Lu J, Gao J, Lu T, Sun J, Jiang H, Zhu Y, Zheng Y, Liang Z, Liu T. Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases. Sci Rep. 2015;5:18678. https://doi.org/10.1038/srep18678https://www.nature.com/articles/srep18678#supplementary-information.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Palomba G, Colombino M, Contu A, Massidda B, Baldino G, Pazzola A, Ionta M, Capelli F, Trova V, Sedda T, Sanna G, Tanda F, Budroni M, Palmieri G, Cossu A. Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. J Transl Med. 2012;10:178. https://doi.org/10.1186/1479-5876-10-178.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Aoyagi H, Iida S, Uetake H, Ishikawa T, Takagi Y, Kobayashi H, Higuchi T, Yasuno M, Enomoto M, Sugihara K. Effect of classification based on combination of mutation and methylation in colorectal cancer prognosis. Oncol Rep. 2011;25:789–94. https://doi.org/10.3892/or.2010.1118.

    Article  PubMed  Google Scholar 

  21. Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res. 2014;20:3033–43. https://doi.org/10.1158/1078-0432.CCR-13-3140.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Piton N, Lonchamp E, Nowak F, Sabourin JC, Christiane M, Marie-Pierre G, Philippe MJ, Pierre D. Real-life distribution of KRAS and NRAS mutations in metastatic colorectal carcinoma from French routine genotyping. Cancer Epidemiol Biomark Prev. 2015;24:1416–8. https://doi.org/10.1158/1055-9965.EPI-15-0059.

    Article  CAS  Google Scholar 

  23. Vakil L, Najafipour R, Rakhshani N, Zamani F, Morakabati A, Javadi A. Investigation of FIH-1 and SOCS3 expression in KRAS mutant and wild-type patients with colorectal cancer. Tumor Biol. 2016;37:8841–8. https://doi.org/10.1007/s13277-015-4723-1.

    Article  CAS  Google Scholar 

  24. Naghibalhossaini F, Hosseini HM, Mokarram P, Zamani M. High frequency of genes’ promoter methylation, but lack of BRAF V600E mutation among Iranian colorectal cancer patients. Pathol Oncol Res. 2011;17:819–25. https://doi.org/10.1007/s12253-011-9388-5.

    Article  CAS  PubMed  Google Scholar 

  25. Mohsen N, Ahmadreza S, Fatemeh H, Fatemeh H, Fariba ER. Frequency of K-RAS and N-RAS gene mutations in colorectal cancers in southeastern Iran. Asian Pac J Cancer Prev. 2016;17:4511–5. http://www.ncbi.nlm.nih.gov/pubmed/27880995

    PubMed  Google Scholar 

  26. A. Koochak, N. Rakhshani, M.H. Karbalaie Niya, F.S. Tameshkel, M.R. Sohrabi, M.R. Babaee, H. Rezvani, B. Bahar, F. Imanzade, F. Zamani, M.R. Khonsari, H. Ajdarkosh, G. Hemmasi, Mutation analysis of KRAS and BRAF genes in metastatic colorectal cancer: a first large scale study from Iran., Asian Pac. J. Cancer Prev. 17 (2016) 603–8. http://www.ncbi.nlm.nih.gov/pubmed/26925650 ().

  27. Z. Ye, W. Guan, T. Tang, F. Wang, … Y.Z.-A. at S., undefined 2019, Gene mutation profiling in chinese colorectal cancers patients and its association with clinicopathological characteristics and prognosis, Papers.Ssrn.Com. (n.d.). https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3405556 ().

  28. Watanabe T, Yoshino T, Uetake H, Yamazaki K, Ishiguro M, Kurokawa T, Saijo N, Ohashi Y, Sugihara K. KRAS mutational status in Japanese patients with colorectal cancer: results from a Nationwide, multicenter, cross-sectional study. Jpn J Clin Oncol. 2013;43:706–12. https://doi.org/10.1093/jjco/hyt062.

    Article  PubMed  Google Scholar 

  29. Goetsch AL, Kimelman D, Woodruff TK. Disorders of the Sex Chromosomes and Sexual Development. In: Disorders of the sex chromosomes and sexual development, in: Fertil. Preserv. Restor. Patients with Complex Med. Cond: Springer International Publishing, Cham; 2017. p. 19–37. https://doi.org/10.1007/978-3-319-52316-3_3.

    Chapter  Google Scholar 

  30. Li W, Qiu T, Zhi W, Shi S, Zou S, Ling Y, Shan L, Ying J, Lu N. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. BMC Cancer. 2015;15:340. https://doi.org/10.1186/s12885-015-1345-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. X. Fu, Y. Huang, X. Fan, Y. Deng, H. Liu, H. Zou, P. Wu, Z. Chen, J. Huang, J. Wang, H. Lin, S. Huang, X. Tan, P. Lan, L. Wang, J. Wang, Demographic trends and KRAS/BRAF V600E mutations in colorectal cancer patients of South China: a single-site report, Int. J. Cancer. (2019) ijc.31973. https://doi.org/10.1002/ijc.31973.

  32. Shen Y, Wang J, Han X, Yang H, Wang S, Lin D, Shi Y. Effectors of epidermal growth factor receptor pathway: the genetic profiling of KRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoS One. 2013;8:e81628. https://doi.org/10.1371/journal.pone.0081628.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Rimbert J, Tachon G, Junca A, Villalva C, Karayan-Tapon L, Tougeron D. Association between clinicopathological characteristics and RAS mutation in colorectal cancer. Mod Pathol. 2018;31:517–26. https://doi.org/10.1038/modpathol.2017.119.

    Article  CAS  PubMed  Google Scholar 

  34. F. Guo, H. Gong, H. Zhao, J. Chen, Y. Zhang, L. Zhang, X. Shi, A. Zhang, H. Jin, J. Zhang, Y. He, Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients, Sci. Rep. 8 (2018). https://doi.org/10.1038/s41598-018-24306-1.

  35. Akman T, Oztop I, Baskin Y, Unek I, Demir N, Ellidokuz H, Yilmaz A. The association of clinicopathological features and survival in colorectal cancer patients with KRAS mutation status. J Cancer Res Ther. 2016;12:96–102. https://doi.org/10.4103/0973-1482.148684.

    Article  CAS  PubMed  Google Scholar 

  36. Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol. 2009;219:435–45. https://doi.org/10.1002/path.2625.

    Article  CAS  PubMed  Google Scholar 

  37. Andreyev HJN, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T. Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer. 2001;85:692–6. https://doi.org/10.1054/bjoc.2001.1964.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Qiu LX, Mao C, Zhang J, Zhu XD, Liao RY, Xue K, Li J, Chen Q. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. Eur J Cancer. 2010;46:2781–7. https://doi.org/10.1016/j.ejca.2010.05.022.

    Article  CAS  PubMed  Google Scholar 

  39. Dolatkhah R, Somi MH, Kermani IA, Bonyadi M, Sepehri B, Boostani K, Azadbakht S, Fotouhi N, Farassati F, Dastgiri S. Association between proto-oncogene mutations and clinicopathologic characteristics and overall survival in colorectal cancer in East Azerbaijan, Iran. Onco Targets Ther. 2016;9:7385–95. https://doi.org/10.2147/OTT.S116373.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Javadi F, Geramizadeh B, Mirzai M. BRAF gene mutation analysis in colorectal cancer in South of Iran. Ann Color Res. 2014;2:1–5.

    Google Scholar 

  41. Molaei M, Farahani RK, Maftouh M, Taleghani MY, Vahdatinia M, Khatami F, Nazemalhosseini-Mojarad E, Aghdae HA, Aboutorabi A, Zali MR. Lack of BRAFV600E mutation in stage I and II of colorectal cancer. Gastroenterol Hepatol from Bed to Bench. 2016;9:94–9.

    Google Scholar 

  42. Brim H, Mokarram P, Naghibalhossaini F, Saberi-Firoozi M, Al-Mandhari M, Al-Mawaly K, Al-Mjeni R, Al-Sayegh A. Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study. Mol Cancer. 2008;7:1–11. https://doi.org/10.1186/1476-4598-7-68.

    Article  Google Scholar 

  43. Asl JM, Almasi S, Tabatabaiefar MA. High frequency of BRAF proto-oncogene hot spot mutation V600E in cohort of colorectal cancer patients from Ahvaz City, Southwest Iran. Pakistan J Biol Sci PJBS. 2014;17:565–9. https://doi.org/10.3923/PJBS.2014.565.569.

    Article  CAS  Google Scholar 

  44. Kwon MJ, Lee SE, Kang SY, La Choi Y. Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue. Pathol Res Pract. 2011;207:762–8. https://doi.org/10.1016/j.prp.2011.10.002.

    Article  CAS  PubMed  Google Scholar 

  45. Yip WK, Choo CW, Leong VC-S, Leong PP, Jabar MF, Seow HF. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia. APMIS. 2013;121:954–66. https://doi.org/10.1111/apm.12152.

    Article  CAS  PubMed  Google Scholar 

  46. Kawazoe A, Shitara K, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, Yamanaka T, Doi T, Ohtsu A, Yoshino T. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer. 2015;15:258. https://doi.org/10.1186/s12885-015-1276-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Hsieh L-L, Er T-K, Chen C-C, Hsieh J-S, Chang J-G, Liu T-C. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population. Clin Chim Acta. 2012;413:1605–11. https://doi.org/10.1016/J.CCA.2012.04.029.

    Article  CAS  PubMed  Google Scholar 

  48. Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer. 2009;101:465–72. https://doi.org/10.1038/sj.bjc.6605164.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One. 2011;6:e22769. https://doi.org/10.1371/journal.pone.0022769.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Rosty C, Young JP, Walsh MD, Clendenning M, Sanderson K, Walters RJ, Parry S, Jenkins MA, Win AK, Southey MC, Hopper JL, Giles GG, Williamson EJ, English DR, Buchanan DD. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS One. 2013;8:e65479. https://doi.org/10.1371/journal.pone.0065479.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, Tsakalaki E, Trypaki M, Messaritakis I, Stathopoulos E, Mavroudis D, Georgoulias V, Souglakos J. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥2nd line Cetuximab-based therapy of colorectal cancer patients. PLoS One. 2011;6:e15980. https://doi.org/10.1371/journal.pone.0015980.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Simi L, Pratesi N, Vignoli M, Sestini R, Cianchi F, Valanzano R, Nobili S, Mini E, Pazzagli M, Orlando C. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol. 2008;130:247–53. https://doi.org/10.1309/LWDY1AXHXUULNVHQ.

    Article  CAS  PubMed  Google Scholar 

  53. Hanna MC, Go C, Roden C, Jones RT, Pochanard P, Javed AY, Javed A, Mondal C, Palescandolo E, Van Hummelen P, Hatton C, Bass AJ, Chun SM, Na DC, Kim T-I, Jang SJ, Osarogiagbon RU, Hahn WC, Meyerson M, Garraway LA, MacConaill LE. Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. PLoS One. 2013;8:e74950. https://doi.org/10.1371/journal.pone.0074950.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Sorbye H, Dragomir A, Sundström M, Pfeiffer P, Thunberg U, Bergfors M, Aasebø K, Eide GE, Ponten F, Qvortrup C, Glimelius B. High BRAF mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort. PLoS One. 2015;10:e0131046. https://doi.org/10.1371/journal.pone.0131046.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Lowe K, Bylsma LC, Levin-Sparenberg ED, Sangaré L, Fryzek J, Alexander DD. Prevalence of KRAS , NRAS , and BRAF gene mutations in metastatic colorectal cancer patients: a systematic literature review and meta-analysis. J Clin Oncol. 2019;37:523–3. https://doi.org/10.1200/jco.2019.37.4_suppl.523.

  56. Clancy C, Burke JP, Kalady MF, Coffey JC. BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis. Color Dis. 2013;15:e711–8. https://doi.org/10.1111/codi.12427.

    Article  CAS  Google Scholar 

  57. Chen D, Huang J-F, Liu K, Zhang L-Q, Yang Z, Chuai Z-R, Wang Y-X, Shi D-C, Huang Q, Fu W-L. BRAFV600E mutation and its association with Clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One. 2014;9:e90607. https://doi.org/10.1371/journal.pone.0090607.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Benvenuti S, Sartore-bianchi A, Di Nicolantonio F, Benvenuti S, Sartore-bianchi A, Di Nicolantonio F, Zanon C. Oncogenic activation of the RAS / RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies oncogenic activation of the RAS / RAF signaling pathway impairs epidermal growth. Fa Cancer Res. 2007;67:2643–8. https://doi.org/10.1158/0008-5472.CAN-06-4158.

    Article  CAS  Google Scholar 

  59. Lee J-H, Ahn J, Park WS, Choe EK, Kim E, Shin R, Heo SC, Jung S, Kim K, Chai YJ, Chae H. Colorectal cancer prognosis is not associated with BRAF and KRAS mutations-a STROBE compliant study. J Clin Med. 2019;8:111. https://doi.org/10.3390/jcm8010111.

    Article  CAS  PubMed Central  Google Scholar 

  60. Eachkoti R, Farooq S, Syeed SI, Wani HA, Majid S, Pampori MR. Prevalence and prognostic relevance of BrafV600E mutation in colorectal carcinomas from Kashmir (North India) valley. Mutagenesis. 2018;33:225–30. https://doi.org/10.1093/mutage/gey008.

    Article  CAS  PubMed  Google Scholar 

  61. Phipps AI, Buchanan DD, Makar KW, Burnett-Hartman AN, Coghill AE, Passarelli MN, Baron JA, Ahnen DJ, Win AK, Potter JD, Newcomb PA. BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomark Prev. 2012;21:1792–8. https://doi.org/10.1158/1055-9965.EPI-12-0674.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank Mohammad Ali Mohammadi (Ph.D. candidate in Biomedicine, Kerman University of Medical Sciences, Iran) for molecular testing guidance.

Funding

This study was supported by the research fund of Kerman University of Medical Sciences (project No. 97000217).

Author information

Authors and Affiliations

  1. Student Research Committee, Kerman University of Medical Sciences, Kerman, Iran

    Abolfazl Yari, Arash Samoudi & Zahra Miri Karam

  2. Department of Pathology, Pathology and Stem Cell Research Center, Afzalipour School of Medicine, Kerman University of Medical Sciences, 22 Bahman Blvd., Kerman, Iran

    Abolfazl Yari, Negin Khaje Karimaldini, Maryam Fekri Soofi Abadi, Mahsa Ziasistani & Shahriar Dabiri

  3. Department of Immunology, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

    Arash Samoudi & Mohammad Reza Zangouey

  4. Department of Medical Laboratory of Sciences, Iran University of Medical Sciences, Tehran, Iran

    Asiyeh Afzali

  5. Physiology Research Center, Kerman University of Medical Sciences, Kerman, Iran

    Zahra Miri Karam

Authors
  1. Abolfazl Yari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arash Samoudi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Asiyeh Afzali
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zahra Miri Karam
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Negin Khaje Karimaldini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maryam Fekri Soofi Abadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mahsa Ziasistani
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mohammad Reza Zangouey
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shahriar Dabiri
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

A.Y conceived and designed the study. A. Y, A.S, Z.M.K and N.K.K performed the experiments and data analysis. A.Y and A.A interpreted the data and drafted the manuscript. M.S.F and Z.M.K helped with sample preparation, patient’s data collection and interpretation. A.Y and M.R.Z helped with statistical analysis. S.D. supervised the findings of this work, reviewed and revised the final manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Shahriar Dabiri.

Ethics declarations

The Ethical Committee of the Kerman University of Medical Sciences approved this research (Approval No. IR.KMU.REC.1397.209).

Conflict of Interests

The authors declare that they have no conflict of interests.

Disclosure Statement

The authors have nothing to disclose.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yari, A., Samoudi, A., Afzali, A. et al. Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran. J Gastrointest Canc 52, 557–568 (2021). https://doi.org/10.1007/s12029-020-00426-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-020-00426-8

Keywords

Search

Navigation